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Introduction: la biopsie du ganglion sentinelle (OS) est une procédure reconnue et fiable pour ét bl' l t d li. •, 
, , . . a tr e s a e gang onrtalte 
du melanome cutane. Le OS est le facteur pronostique le plus pmssant pour la survie des patients atteints d'un mélano 
risque intermédiaire, cliniquement localisé. Celui-ci est métastatique dans environ 15-30% des cas. Lorsque le 0 ;1:st 
positif, un curage de l'aire ganglionnaire concern.ée est généralement entrepris. Néanmoins, seuls 20-25% de ces patients 
présentent des ganglions non-sentinelles (ONS) métastatiques. Ces données suggèrent que le curage, et les risques 
opératoires qui y sont associés, n'est peut-être pas nécessaire chez le trois-quarts de ces patients. Un autre aspect est que 
l'impact sur la survie des curages basé sur le résultat du OS n'est pas clairement démontré. La nécessité de ce curage 
d'emblé est actuellement en cours d'évaluation par un protocole international (Multicenter Selective Lymphadenectomy 
Trial II: MSLT II). Plusieurs auteurs ont essayé de classifier la charge tumorale du OS afin d'évaluer s'il était possible 
d'épargner le curage à certains patients et de mieux affiner ce facteur pronostic sans succès. En 2009, le Groupe Mélanome 
de l'EORTC (European Organisation for Research and Treatment of Cancer) a recommandé un protocole d'évaluation 
anatomopathologique du OS-positif en trois items: (1) la localisation micro-anatomique des métastases à l'intérieur du 
ganglion selon Dewar (A= sous-capsulaire, B =combinée sous-capsulaire and parenchymateuse, C =parenchymateuse, D 
= multifocale, and E =extensive); (2) la mesure de la taille tumorale dans le ganglion selon les critères de Rotterdam pour 
le diamètre maximal. Le diamètre de la plus grande métastase est exprimé en nombre absolu et (3) la taille tumorale 
stratifiée par catégories : <0. lmm, 0.1-1.0mm et> 1.0 mm. Le but de cette étude rétrospective d'une cohorte de patients, 
était d'investiguer les résultats des OS-positifs et d'analyser les facteurs pronostiques de la survie à la lumière des 
recommandations de l'EORTC. Ainsi que de comparer les sous-groupes du OS-positif avec une invasion minimale (taille 
tumorale <0. lmm et/ou atteinte sous-capsulaire) avec le OS-négatif. Les facteurs pouvant prédire la présence de GNS-
positifont également été analysés. 
Matériel et méthode : une étude des dossiers a été réalisée pour les 499 patients consécutifs entre 1997 et 2008 qui ont eu 
une biopsie du OS dans notre institution. Le dégrée d'envahissement du OS-positif a été entièrement revue par l'équipe 
référente de l'Institut de Pathologie (Dresse E. Saiji et Dresse H. Bouzourène) selon les recommandations de l'EORTC. Des 
analyses univariées et multivariées des potentiels facteurs pronostics ont été réalisées. Des analyses de survie ont également 
été effectuées avec des courbes d'estimation de Kaplan-Meier combinées à une régression de Cox. Le protocole a été 
accepté par la Commission d'Ethique. 
Résultats: un OS-positif a été trouvé chez 123 (25%) patients parmi les 499 qui ont bénéficié d'une biopsie. Avec un suivi 
médian de 52 mois, la survie à 5 ans sans récidive (SSR), spécifique à la maladie (SS) et globale (SO) étaient de 88%, 94%, 
et 90% respectivement pour les patients avec OS-négatif. Concernant les OS avec invasion minimale, 21 patients étaient 
dans le sous-groupe <0.1 mm selon les critères de Rotterdam et 52 patients dans le sous-groupe sous-capsulaire selon 
Dewar. La survie dans ces deux sous-groupes était de 80% et 57% pour la SSR, 87% et 70% pour la SS, 87% et 68% pour 
la SO, respectivement. L'analyse multivariée des OS-positifs a montré que les facteurs suivants influençaient 
significativement la survie (SSR, SS et SO): l'épaisseur selon Breslow de la tumeur primaire (p=0.002, 0.006, 0.004), la 
taille tumorale du OS-positif:?:O. lmm (p= 0.01, 0.04, 0.03), le genre masculin (p=0.06, 0.005, 0.002) et l'ulcération de la 
tumeur primaire (p=0.05, 0.03, 0.007). L'analyse des sous-groupes avec invasion minimale n'a pas permis d'établir de 
facteur pour prédire la négativité des ONSs. 
Conclusion: La classification du OS-positif par la taille tumorale selon les critères de Rotterdam est un facteur pronostique 
simple et utile pour évaluer la survie des patients atteints de mélanome. Nous avons observé une tendance (non 
statistiquement significative) d'une smvie diminuée pour le sous-groupe des patients avec OS-positif et une taille de la 
métastase <O.lmm comparée à celle des patients avec OS-négatif. C~ci nous incite à conclure que ce sous-groupe de 
patients ne devrait pas être assimilé et traité comme ceux qui ont un OS-négatif. D'autre part nos résultats montrent que la 
localisation micro-anatomique selon Dewar n'est pas un outil pronostique utile pour évaluer la smvie, ni pour prédire le 
status des GNSs. 
Jou mal of Cancer Tlterapy, 2013, 4, 1490-1498 
Published Online December 2013 (http://www.scirp.org/journal/jct) 
http://dx.doi.org/l 0.4236/jct.2013.4!0180 
Scientific 
Research 
The Prognostic Value of Minimally Involved Melanoma 
Sentine! Lymph Nodes * 
Alend Saadi1#, Didier Roulin1#, Essia Saiji2, Hanifa Bouzourene2, Nicolas Demartines1, 
Maurice Matter1t 
1Depat1ment of Visceral Surge1y, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; 2University lnstitute of Pathol-
ogy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. 
Email: tmaurice.matter@chuv.ch 
Received November 261h, 2013; revised December 171h, 2013; accepted December 23'ct, 2013 
Copyright© 2013 Alend Saadi et al. This is an open access article distributed under the Creative Commons Attribution License, 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In accor-
dance of the Creative Commons Attribution License ail Copyrights© 2013 are reserved for SCIRP and the owner of the intellectual 
property Alend Saadi et al. Ali Copyright© 2013 are guarded by law and by SCIRP as a guardian. 
ABSTRACT 
Background: Sentine! node (SLN) status is the most important prognostic factor for early-stage melanoma patients. It 
will influence follow-up and may change therapy. Positive SLNs present different degrees of involvement so that sub-
groups of patients may have minimal SLN invasion. The aim of this study was to evaluate survival in subgroups with 
minimally involved SLNs and to compare them to negative SLN patients. Method: SLN biopsy was performed in 499 
consecutive clinically NO patients between 1997 and 2008. Following updated recommendations from the Melanoma 
Group of the European Organization of Research and Treatment of Cancer, degrees of SLN involvement were fully re-
assessed for two anatomopathological parameters: tumour burden according to Rotterdam criteria ( <0.1 mm, 0.1 - 1.0 
mm, and > 1.0 mm) and microanatomic location according to Dewar (subcapsular, combined subcapsular and paren-
chymal, parenchymal, multifocal, or extensive). Minimally involved SLNs were defined as those with tumor burden 
<0.1 mm and/or subcapsular metastasis location. Kaplan-Meier and multivariable logistic regression analyses were per-
formed. Results: Out of 499 clinically NO patients, positive SLNs were found in 123 patients (24.7 percent). With a 
median follow-up of 52 months (range: 9 - 146), five-year disease-free (DFS), disease-specific survival (DSS) and 
overall survival (OS) were 88.1, 93.9 and 89.9 percent for negative SLN patients, respectively. In minimally involved 
SLNs, there were 21 with tumour burden <0.1 mm, and 52 with subcapsular metastasis. Five-year DFS, DSS and OS in 
these sub-groups were 79.6, 86.6 and 86.6 percent, then 57.3, 69.8 and 67.8 percent respectively. DFS univariable 
analysis ofthese sub-groups compared to negative SLNs showed: (HRl.89, 95 percent CI 0.75 - 4.79; p 0.175) and (HR 
3.92, 95 percent CI 2.29 - 6.71; p < 0.0001) respectively. Minimally involved sub-groups were not predictive for NSLN 
negativity. Conclusion: Rotterdam's tumour burden stratification is an easy and useful prognostic factor ofmelanoma 
survival. There was a trend showing that patients with SLN tumour burden <0.1 mm have a lower survival compared to 
SLN negative patients. One might suggest that patients with minimally involved SLNs may not be managed similarly to 
negative SLN patients. Subcapsular metastasis subgroup according to the microanatomic location has statistically sig-
nificant worst survival. 
Keywords: Metastatic Melanoma; Sentine! Node; Minimally Involved 
1. Introduction 
Since the first rep01t in 1992 for melanoma patients [1], 
sentine! lymph node (SLN) biopsy has become a routine 
procedure in specialized centers for the management of 
*sources of support and funding for this work: none. 
#Both authors contributed equally to this work. 
tcorresponding author. 
Open Access 
intermediute risk, clinically localized cutaneous mela-
noma. Lymphatic mapping with sentine! lymphadenec-
tomy is a safe and effective surgical technique with lim-
ited morbidity [2]. The imp01tance of the SLN status is 
now widely accepted as the most important prognostic 
factor [2,3]. In literature, positive SLN is found in 15 
percent to 30 percent of patients [3-8]. In case of positive 
JCT 
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SLN, most centers recommend a completion lymph node 
dissection (CLND). However, additional positive non-
sentinel lymph nodes (NSLN) are found in only about 20 
percent of CLND [3,5,7-10]. This means that radical 
lymph node dissection, with its consecutive morbidity 
[11], might be unnecessary in about three quarters of 
patients with positive SLN. Seeking for the optimal prac-
tice, the SLN status was sharpened in order to better pre-
dict NSLN status, recurrence rate and survival. Different 
classifications of positive SLN were proposed but none 
of these have gathered a wide acceptance [ 5, 7-17]. Re-
cently, the EORTC Melanoma Group recommended a 
protocol to report the three following items per positive 
SLN [18]: (1) The microanatomic location of the metas-
tases according to Dewar for the entire node (A = sub-
capsular, B = combined subcapsular and parenchymal, C 
= parenchymal, D = multifocal, and E = extensive); (2) 
the SLN tumour burden according to the Rotterdam Cri-
teria for the maximum diameter of the largest metastasis 
expressed as an absolute number; and (3) the SLN tu-
mour burden stratified per category: <0.1 mm, 0.1 - 1.0 
mm, or>l.O mm. 
The aim of this retrospective study of a prospective 
cohort was to analyze the results of the positive SLNs in 
a tertiary reference center for melanoma, to investigate 
prognostic factors for disease-free survival (DFS), dis-
ease-specific survival (DSS) and overall survival (OS) in 
light of the EORTC recommendations protocol and pri-
mary tumour criteria, and to compare minimally involved 
subgroups, such as tumour burden <0.1 mm, subcapsular 
metastasis, and SLN negative patients. Predictability of 
positive NSLNs was also analyzed. 
2. Patients and Methods 
2.1. Patients 
Between October 1997 and December 2008 all consecu-
tive SLN biopsy (SLNB) for melanoma patients were 
included prospectively in a database. SLNB was per-
fonned by a single surgical team at the Centre Hospi-
talier Universitaire Vaudois (CHUV) in Switzerland. 
Inclusion criteria were primmy skin melanoma > 1.00 
mm without palpable adenopathy and absence of distant 
metastases (confirmed by CT scan or PET scan). Patients 
with melanoma thickness <1.00 mm in the presence of 
specific histopathologic factors, such as ulceration, re-
gression, or Clark lev el IV /V were also included. A 
CLND was usually proposed to patients with metastatic 
SLN. Patients with clinically metastatic lymph nodes 
were offered a therapeutic lymph node dissection and 
excluded from the present analysis. Patients with local 
recurrence of an earlier melanoma who also had a SLNB 
were excluded. The protocol of this study was accepted 
by the Institutional Ethical Committee. 
Open Access 
2.2. Surgical Technique and Pathological 
Analysis 
All patients underwent SLNB according to the triple 
technique as previously described (3). The SLN was de-
fined as any blue node, the node with the highest radio-
active count, and any node with > 10 percent count rate of 
the most radioactive node. Any enlarged (> 1 cm) suspi-
cious node and some adjacent nodes (mainly for ana-
tomical reason) were also dissected. SLNB was followed 
by initial melanoma scar wide excision (WE) with safety 
margins of 1 cm and 2 cm according to Breslow thick-
ness of<= 1 mm and >1 mm respectively. SLN(s) were 
sent fresh or in formaldehyde solution directly to the 
University lnstitute of Pathology. Lymph nodes were 
bivalved and paraffin embedded. Three slices were eut 
for hematoxylin and eosin (H & E) and immunohisto-
chemistry (IH) staining (Melan A and protein SlOO) at a 
regular 50 µm interval at least six tiJnes following a 
SLNB protocol (3). No PCR analysis was performed. 
The CLND's nodes were only processed with H-E stain-
ing. An expert team from the Department of Pathology 
(E.S. & H.B.) reviewed all positive SLNs for the purpose 
ofthis study, according to the EORTC Melanoma Group 
recommended protocol [18]. Degrees of SLN involve-
ment were fully re-assessed for two anatomopathological 
parameters: tumour burden according to Rotterdam crite-
ria (<0.1 mm, 0.1 - 1.0 mm, and >1.0 mm) and microan-
atomic location according to Dewar (subcapsular, com-
bined subcapsular and parenchymal, parenchymal, mul-
tifocal, or extensive). Minimally involved SLNs were 
defined as those with tumor burden <0.1 mm and/or sub-
capsular metastasis location. 
2.3. Follow-Up 
A clinicat follow-up was performed every 3 months dur-
ing the first year after diagnosis, every 4 months during 
h d ' h 3rd 4th d 5th the second year, every 6 mont s unng t e , an 
years and then once a year. For patients with a Breslow 
more than 4 mm and for patients with positive SLN, a 
thoraco-abdominal scan was done once a year during the 
first five years following diagnosis. Most patients were 
followed at the outpatient clinic of the Oncology Unit in 
the same institution. Sorne patients were followed by 
their own dermatologists; their written follow-up was 
obtained after consent. Duration of follow-up was de-
fined as tune between date of SLN procedure and date of 
the last follow-up or death. 
2.4. Statistical Analysis 
Quantitative variables were compared using the Student 
or the Mann-Whitney test. Categorical variables were 
compared using the x2 test. Univariable analysis of po-
tential prognostic factors was performed (Table 1). A 
JCT 
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Table 1. Clinical and anatomopathological characteristics of 123 positive sentine) lymph nodes (SLNs) patients and univari-
able analyses of disease-free (DFS), disease-specific (DSS) and overall survival (OS). 
Characteristics 
Gender 
Level 
Female 
Male 
:S65 years 
50 
73 
J{R 
1 
2.14 
DFS 
95%CI P HR 
1 
1.2 - 3.8 0.008 2.57 
1 
DSS 
95% CI 
1.2 - 5.3 
p 
0.011 
HR 
1 
2.58 
os 
95% CI p 
1.3 - 5.1 0.007 
Age (mean) 
>65 years 
84 
39 
1 
1.68 1.0 - 2.83 0.052 1.50 0.8 - 2.9 0.230 
1 
1.57 0.9 - 2.9 0.153 
Melanoma subtype 
Breslow thickness 
Clark level 
Ulceration 
Primary melanoma 
location 
Lymph node basin 
Superficial spreading 
Nodular 
Acral lentiginous 
Others 
<l mm 
1.01 - 2.0 mm 
2.01 - 4.0 111111 
>4.0 mm 
III 
IV 
V 
Absent 
Present 
Extremity 
Head and neck 
Trunk 
42 
50 
15 
16 
4 
41 
49 
29 
23 
89 
11 
49 
74 
63 
5 
55 
92 
31 
1 
1.05 
1.63 
0.76 
1 
1 
1.82 
1.82 
1 
1.23 
1.37 
1 
2.21 
1 
1.68 
1.09 
1 
1.08 
0.6 - 1.9 
0.7 - 3.6 
0.3 - 1.9 
1.3 - 2.5 
1.3 - 2.5 
0.6-2.5 
0.5 - 3.8 
1.3 - 3.7 
0.5 - 5.5 
0.7 - 1.8 
0.6 - 1.9 
1 
0.870 1.22 
0.220 1.82 
0.545 0.95 
1 
1 
<0.0001 3 .68 
<0.0001 3.68 
1 
0.552 1.41 
0.551 1.21 
1 
0.003 2.16 
1 
0.6 - 2.5 
0.6 - 5.2 
0.3 - 3.0 
1.1 - 2.3 
1.1 - 2.3 
0.6 - 3.4 
0.3 - 4.9 
1.1 - 4.1 
0.601 
0.265 
0.935 
0.002 
0.002 
0.440 
0.787 
0.018 
0.393 2.93 0.9 - 10.1 0.089 
0.729 1.50 0.8 - 2.9 0.226 
1 
0.789 1.26 0.6 - 2.6 0.530 
1 
1 
1.24 
1.67 
1.10 
1 
1 
1.64 
1.64 
1 
1.56 
1.63 
1 
2.38 
1 
0.6 - 2.5 
0.6 - 4.7 
0.4-3.1 
1.1 - 2.4 
1.1 - 2.4 
0.7 - 3.7 
0.5 - 5.9 
1.3 - 4.3 
0.544 
0.331 
0.861 
0.008 
0.008 
0.316 
0.448 
0.005 
2.41 0.7 - 8.2 0.157 
1.32 O. 7 - 2.5 0.379 
1 
1.41 0.7 - 2.7 0.314 
1 
SLN Tumour Burden 
>! 
<0.1 mm 
0.1 - 1 mm 
> 1.0 mm 
21 
33 
65 
4 
1 
2.58 
4.50 
0.9 - 7.3 
1.8 - 11.5 
0.076 2.14 0.7 - 6.9 0.203 
0.002 3.35 1.2- 9.7 0.026 
2.11 0.7 - 6.8 0.211 
3.69 1.3 - 10.6 0.015 
SLN Microanatomic 
tumour location' 
Not available 
A 
B 
c 
D 
E 
Not available 
52 
18 
Il 
8 
29 
5 
1 
1.45 
0.74 
1.32 
3.31 
0.7 - 3.2 
0.2- 2.5 
0.5 - 3.9 
1.7 - 6.1 
1 
0.363 1.57 
0.635 0.94 
0.611 0.39 
<0.0001 1.98 
0.6 - 3.9 
0.3 - 3.3 
0.05 - 3.0 
0.9 - 4.3 
0.327 
0.927 
0.367 
0.081 
1 
1.69 
0.88 
0.37 
1.97 
0.7-4.0 
0.3 - 3.0 
0.05 - 2.8 
1.0 - 4.1 
0.232 
0.841 
0.334 
0.070 
'SLN Microanatomic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, multifocal or E, 
extensive. HR, hazard ratio. CI, confidence interval. P, significance level. 
multivariable logistic regression model was used for the 
significant factors in the univariable analyses. Survival 
analyses involved the Kaplan-Meier method combined 
with log-rang test and multivariable Cox's proportional 
hazard regression models. Statistical analyses were per-
fonned with Stata 11 software (Stata Corp®). P values 
less than 0.05 were considered statistically significant. 
3. Results 
3.1. Patient Characteristics 
During the study period, 499 consecutive patients with 
primary skin melanoma and clinically NO underwent a 
SLNB and were included in this study. Metastases to 
SLN(s) were detected in 123 (24.7 percent) patients. The 
median (range) Breslow thickness was 1.7 mm (0.3 - 15), 
1.5 mm (0.3 - 15), and 2.5 mm (0.8 - 12) for all patients, 
SLN negative and SLN positive patients respectively. 
Open Access 
For the same groups of patients, male ratios were 274/ 
499 (55 percent), 201/376 (54 percent) and 73/123 (59 
percent) respectively; ulceration rates were 126/499 (25 
percent), 77/376 (21 percent), 49/123 (40 percent) re-
spectively. Clinical and anatomopathologie characteris-
tics of the 123 SLN positive patients are presented in 
Table 1. All positive SLN were classified according to 
the recommendations from the EORTC Melanoma 
Group protocol published in 2009 (15). In four cases the 
pathological slides were not available for reassessment of 
the tumour burden and in five cases for the micro-
anatomic location. The four SLN positive patients who 
had melanoma with Breslow thickness ~1.0 mm had a 
Breslow thickness close to 1.0 mm (n = 2) or Clark level 
IV (n=2). 
3.2. Prognostic Factors 
The univariable Cox's analysis of the 123 SLN positive 
JCT 
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patients for DFS, DSS, and OS are presented in Table 1. 
Breslow thickness >2.0 mm, male gender, ulceration, 
SLN tumour burden >= 0.1 mm, and extensive micro-
anatomic metastatic location (E) were significantly asso-
ciated with worse DFS, DSS, and OS (p < 0.05). A11 age 
> 65 years was also significantly associated with worse 
DFS. On the multivariable analysis, Breslow thickness 
>2.0 mm (HR 3.01, 95 percent CI 1.51 - 6.04; p 0.002/ 
HR 3 .27, 95 percent CI 1.40 - 7 .66; p 0.006/HR 3 .46, 95 
percent CI 1.49 - 8.05; p 0.004), ulceration (HR 1.74, 95 
percent CI 0.99 - 3.06; p 0.054/HR 2.13, CI 1.07 - 4.27; p 
0.032/HR 2.50, 95 percent CI 1.28 - 4.89; p 0.007), and 
SLN tumour burden >= 0.1 mm (HR 3.55, 95 percent CI 
1.30 - 9.66; p 0.013/HR 3.04, 95 percent CI 1.03 - 8.94; p 
0.044/HR 3.29, 95 percent CI 1.12 - 9.66; p 0.030) were 
independent significant factors lowering DFS, DSS, and 
OS. Male gender (HR 1.81, 95 percent CI 0.98 - 3.32; p 
0.057/HR 2.95, 95 percent CI 1.39 - 6.27; p 0.005/HR 
3.32, 95 percent CI 1.58 - 7.0; p 0.002) was an inde-
pendent significant factor lowering DSS and OS. Exten-
sive microanatomic metastatic location (E) was an inde-
pendent significant factor lowering only DFS (HR 1.87, 
95 percent CI 1.05 - 3.35; p 0,033). The median SLN 
tumour burden in the extensive microanatomic location 
(E) was 7 mm (range: 0.8 - 15) compared to 0.15 mm 
(range 0.09 - 4) in the subcapsular microanatomic loca-
tion (A) (HR 3.31, 95 percent CI 1.7 - 6.1; p < 0.001). 
3.3. Survival Analyses 
The median follow-up time for ail 499 patients was 52 
months (range: 9 - 146). The median follow-up tüne for 
the 123 SLN positive patients was 41 months (range: 2 -
146). The 3- and 5 - year DFS for SLN positive patients 
were 57.8 percent and 47.6 percent, compared to 92.3 
percent and 88. l percent respectively for patients with a 
negative SLN. The 3- and 5-years DSS were 77.2 percent 
and 61.8 percent compared to 97.2 percent and 93.9 per-
cent; and OS were 75.4 percent and 59.1 percent com-
pared to 95.4 percent and 89.9 percent for the same pa-
tients respectively. 
3.4. Sentinel Lymph Node Positive Subgroups 
Analyses 
SLN positive subgroups DFS, DSS, and OS compared to 
negative SLN are presented in Table 2. SLN tumour 
burden subgroups 0.1 - 1 mm and > 1 mm were signifi-
cantly associated with worse survival. However, it did 
not reach statistical significance for the <0.1 mm sub-
group. SLN microanatomic tumour location subgroups 
were ail constantly significantly associated with a poorer 
survival, except for subgroups C and D. The 3- and 
5-years DFS, DSS, and OS for SLN positive subgroups 
compared to SLN negative patients are presented in Ta-
ble 3. Tumour burden subgroups disease-free survival 
curves are shown in Figure 1. Global recurrence rate was 
5 (24 percent), 14 (42 percent), and 43 (66 percent) for 
Rotterdam subgroups <0.1 mm, 0.1 - 1 mm, and >1 mm 
respectively. Minimally involved SLN subcapsular sub-
group A presented 20 recurrences (39 percent). There 
were 45 recurrences (12 percent) in the negative SLN. 
3.5. Predictive Factors for Non-Sentinel Lymph 
Node Metastasis 
Among the 123 patients with a positive SLN, 111 un-
derwent a CLND. The procedure was not proposed to 
Table 2. Univariable analyses of sentine! lymph node (SLN)-positive subgroups of disease-free (DFS), disease-specific (DSS) 
and overall survival (OS) compared to SLN negative patients. 
DFS DSS os 
SLN status Level N 
HR 95%CI p HR 95% CI p HR 95% CI p 
SLN negative 376 
<0.1 mm 21 1.89 0.75 - 4.79 0.175 2.42 0.84 - 6.95 0.100 1.43 0.51 - 3.99 0.493 
SLNTumour 0.1 - 1.0 mm 33 4.55 2.45 - 8.47 <0.0001 5.41 2.60 - 11.26 <0.0001 3.29 1.65 - 6.56 0.001 Burden 
>1.0 mm 65 8.97 5.83 - 13.80 <0.0001 8.88 5.08 - 15.56 <0.0001 6.04 3.72 - 9.79 <0.0001 
A 52 3.92 2.29 - 6.71 <0.0001 3.20 2.64 - 9.44 <0.0001 4.10 1.81 - 5.68 <0.0001 
B 18 6.07 2.96 - 12.48 <0.0001 5.55 3.57 - 19.27 <0.0001 8.30 2.60 - 11.86 <0.0001 
SLN 
Micro anatomie c 11 2.71 0.84 - 8.75 0.095 2.97 1.44 - 15.83 0.069 4.78 0.92 - 9.59 0.010 
tumour location . 
D 8 5.08 1.82-14.17 0.002 1.08 0.25 - 13.68 0.942 1.85 0.15 - 7.82 0.545 
E 29 13.93 8.38 - 23.17 <0.0001 7.02 5.31 - 21.18 <0.0001 10.60 3.75 - 13.14 <0.0001 
·sLN Microanatomic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, multifocal or E, 
extensive. HR, hazard ratio. CI, confidence interval. P, significance level. 
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Figure 1. Kaplan-Meier curves with log-rank test of tumour burden subgroups disease-free survival compared to negative 
sentine! nodes patients. 
Table 3. Sentine! lymph node (SLN) subgroups primary characteristics: Breslow thickness (median and range) and ulcera-
tion, the 3 and 5 years rates of disease-free (DFS), disease-specific (DSS) and overall survival (OS). 
3 years 5 years 
SLN status Level Breslow u 
DFS DSS os DFS DSS os 
SLN negative 1.5 (0.3 - 15) 20% 92.3 97.2 95.4 88.1 93.9 89.9 
<0.1 mm 2.3 (1.1 - 9) 38% 86.3 93.4 93.7 79.6 86.6 86.6 
SLN Tumour Burden 0.1-1 mm 2.0 (1.0 - 6) 30% 64.4 83.1 83.4 52.7 68.7 68.5 
>!mm 3.0 (0.8 - 12) 48% 43.3 69.2 65.3 32.1 50.2 44.9 
A 2.4 (1.0 - 9) 37% 68.4 83.4 82.6 57.3 69.8 67.8 
B 2.8 (1.1 - 8) 33% 56.9 72.6 67.4 45.0 54.8 47.9 
SLN Microanatomic c 2.0 (1.2 - 6) 36% 78.4 84.2 84.5 69.2 71.0 70.8 Tumour location . 
D 2.7 (1.5 - 5) 38% 65.9 94.0 94.3 54.5 87.9 88.0 
E 3.1 (0.8 - 12) 52% 32.0 66.7 63.9 22.6 47.9 44.0 
'sLN Microanatomic Tumour location according Io Dewar (8): A, subcapsular, B, cornbined subcapsular and parenchymal, C, parenchyrnal, D, rnultifocal, or E, 
extensive. U, ulceration. 
three patients due to their poor general condition, and six 
further patients refused the procedure. A CLND was also 
not proposed to three patients between 1997 and 2000 
due to the ve1y limited SLN invasion. Their SLNs were 
negative with H-E and had few metastatic cells detected 
Open Access 
in IH. One or more (median = 1, range = 1 - 4) positive 
non-sentinel nodes (NSLN) were found in 20 patients (18 
percent). The univariable analysis of these patients is 
presented in Table 4. On the multivariable analyses, ul-
ceration (OR 6.51, 95 percent CI 1.91 - 22.13; p = 0.003) 
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Table 4. Predictive factors of positive non-sentinel lymph nodes (NSLNs). 
Positive NSLN = 20 Negative NSLN = 91 
Characteristics Level 
N % N % OR p 
Gender Fe111ale ·8 18 37 82 1 Male 12 18 54 82 1.03 0.957 
Age ( 111ean ) :S 65 years 11 14 65 86 1 
> 65 years 9 26 26 74 2.04 0.157 
Superficial spreading 5 12 36 88 1 
Melano111a subtype Nodular 11 25 33 75 2.40 0.138 Acrallentiginous 2 18 9 82 1.60 0.608 
Others 2 13 13 87 1.11 0.909 
<1111111 0 4 100 1 
Breslow thickness 1.01 - 2.0 111111 4 10 37 90 1 2.01 - 4.0 111111 11 28 29 73 1.57 0.135 
>4.0 111111 5 19 21 81 1.57 0.135 
Clark level III 3 14 19 86 1 IV and V 17 19 72 81 1.50 0.552 
Ulceration Absent 6 9 60 91 1 Present 14 31 31 69 4.52 0.005 
Pri111ary 111elano111a loca- Extre111ity 10 18 45 82 1 Head and neck 3 60 2 40 6.75 0.051 tion Trunk 7 14 44 86 0.72 0.533 
<0.1111111 1 6 16 94 1 
SLN Tu111our Burden 0.1 - 1 111111 5 17 25 83 3.20 0.308 
>1.0 111111 12 20 49 80 3.92 0.206 
Not available 2 1 
A 6 13 40 87 1 
B 2 13 14 87 0.95 0.955 
SLN Microanato111ic c 2 22 7 78 1.90 0.481 
Tu111our location . D 0 0 7 100 
E 8 28 21 72 2.54 0.123 
Not available 2 2 
'sLN Microanato111ic tumour location according to Dewar (8): A, subcapsular. B, combined subcapsular and parenchymal. C, parenchymal. D, 111ultifocal or E, 
extensive. OR, odd ratio. P, significance level. 
and primary local tumour in the head and neck (OR 
17.83, 95 percent CI 2.02 - 157.90; p = 0.010) were sig-
nificant predictive factors for NSLN positivity. The de-
gree of SLN involvement, with both studied classifica-
tions, was not a predictive factor of NSLN positivity. 
Among the 12 patients who did not undergo a CLND, 
four were in the minimally involved <0.1 mm subgroup 
and two of them recurred at 2 months and 4 years then 
deceased at 2 and 5 years respectively, another six pa-
tients were in the minimally involved subcapsular mi-
croanatomic location (A) and four of them recurred at 2, 
5, 6, and 24 months while three ofthem deceased at 1, 2, 
and 3 years. 
4. Discussion 
This single-institution-based study with surgical and an 
atomopathological dedicated teams confinned that tu-
mour burden stratification according to Rotterdam crite-
ria is a useful prognostic factor for survival. Patients with 
SLN tumour burden <0.1 mm have a trend toward lower 
survival and toward higher recurrence rate, compared to 
Open Access 
SLN negative patients. 
The clinical and anatomopathologie characteristics of 
SLN positive patients in this study are comparable to 
those described in literature [7-10,13,15] in terms of age, 
primary melanoma location, male/female ratio, Clark 
level, and ulceration rate. However, the median Breslow 
thickness was 1.7 mm for ail patients, and 2.45 mm for 
SLN positive patients. These Breslow data are among the 
lowest mentioned in literature [7,13,15], indicating that 
primary tumours were probably detected at an earlier 
stage. Despite this, 24.7 percent of metastatic SLN were 
detected in clinically negative patients, which is among 
the highest published rate [7-10,13,15]. The positive 
NSLN rate is comparable to those previously reported. 
The microanatomic location classification according to 
Dewar was intended to predict NSLN metastatic in-
volvement in the CLND following a SLNB procedure [5]. 
The subgroup with subcapsular metastasis (A) is consid-
ered to be in the early stage of metastatic invasion, with 
the hypothesis that metastatic cells have not yet contin-
ued to NSLN. However, in this study, 13 percent of the 
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1496 The Prognostic Value ofMinimally Involved Melanoma Sentine! Lymph Nodes 
patients with subcapsular metastasis presented a positive 
NSLN. Compared to negative SLN patients, the sub-
groups A, B, and E were associated with a higher recur-
rence rate and a poorer survival. The subgroups C and D 
comprised of such a small number of patients that they 
were therefore probably not associated with a poorer 
survival than negative SLN patients. 
Only subgroup E, with extensive metastasis, was an 
independent significant factor on multivariable analysis 
and negatively affected DFS. This was in fact partially 
related to the diameter, with a median SLN tumour bur-
den significantly higher in the subgroup E compared to 
subgroup A. Additionally, the distribution of the different 
subgroups in this present study differed from its original 
description: we found 42 percent of patients with sub-
capsular metastasis (i.e. subgroup A), as compared to 26 
percent in Dewar's publication. This can be explained by 
the fact that this cohort of patients seems to have been 
diagnosed at an earlier stage. One may also hypothesize 
that the Dewar classification is difficult to reproduce, 
despite the fact that expert pathologists (ES, HB) pre-
cisely reviewed all slides. This suggests that microana-
tomic location is not a useful tool for predicting survival 
or the NSLN status. 
Van Akkooi's Rotterdam Criteria was specifically de-
signed for survival analysis [7]. He convincingly demon-
strated that the tumour burden threshold for SLN sub-
micrometastases in melanoma should be <0.1 mm. With 
a slightly higher eut-off of <0.2 mm, the future of these 
patients is differed significantly [15]. Tumour burden 
within SLN is indeed an easy way to classify the degree 
of the SLN metastatic invasion in contrast to many other 
complicated classifications [16, 19-21]. In his first publi-
cations, Van Akkooi concluded that sub-micrometastases 
<0.1 mm could be considered as biologically false posi-
tive, identical to SLN negative patients. Therefore, these 
patients could be spared a CLND and could be included 
into adjuvant therapy trials as SLN negative patients 
[7 ,22]. Van der Ploeg et al. [8-1 O] confirmed these con-
clusions in the same institution, and mentioned seven 
patients from 2004 to 2008 who did not undergo CLND 
because of the presence of minimal SLN tumour burden 
( <0.1 mm). By interest, the issue of minimally involved 
SLN was initially also debated in this institution. Three 
among the earlier patients treated in this cohort were not 
proposed a CLND. ln the present study, only tumour 
burden > = 0.1 mm was a significant independent factor 
worsening DFS, DSS and OS. Sub-micrometastases 
(<0.1 mm) was not a significant independent factor for 
survival. However, there was a trend towards worse out-
comes for patients with sub-micrometastases in com-
parison to SLN negative patients. It could be hypothe-
sized that this trend did not reach statistical significance 
due to the small number of patients (21 in the sub-mi-
Open Access 
crometastatic subgroup ), therefore not permitting a gen-
eralization on a larger scale. Global recurrence rates also 
rose following an increase of the metastatic charge ex-
pressed as tumour burden. However, even in the sub-
micrometastatic group, five patients recurred: four pa-
tients presented initially local recurrence, and one patient 
had directly distant metastases. Only one patient in sub-
micrometastatic subgroup had a positive NSLN. The 
Rotterdam criteria satisfactory allow a stratification of 
the prognosis of patients with positive SLN. Although 
CLND did not influence survival in cohort studies [23], 
there is no data from randomized controlled trials. That is 
why; the issue remains debated waiting for the ongoing 
prospective study MLST II results. The European con-
sensus multidisciplinary based guideline 2012 did not eut 
the issue of CLND for sub-micrometastatic subgroup 
[24]. 
Sorne authors attempted to integrate various elements 
in scores, taking into account the primary melanoma 
characteristics and the metastatic charge of the SLN, but 
until now these scores failed to reach two goals. The first 
one is to find out the least invasive but the most secure 
care program for a subgroup of positive SLN who are 
unlikely to recur and have similar survival compared to 
negative SLN. The second goal is to identify patients 
with micrometastatic SLNs who have no positive NSLN 
and thus can be considered as negative SLN. Taking into 
account the present clinical data, one would challenge at 
this point that such a classification might be possible. As 
shown in this study, even a very limited SLN invasion 
had a trend toward lower survival and could be associ-
ated with positive NSLN. If other primary tumour char-
acteristic restrictions are added to the sub-microscopic 
subgroup, a real subgroup acting as negative SLN might 
be found. ln this case, it would restrict this subgroup so 
much that it would apply to a very limited number of 
patients and thus lose its clinical significance. 
5. Conclusion 
Tumour burden stratification according to Rotterdam 
criteria is an easy and useful prognostic factor of survival 
in melanoma. There was a trend showing that patients 
with SLN sub-micrometastases <0.1 mm had a lower sur-
vival compared to SLN negative patients. One might 
suggest that patients with minimally involved SLNs may 
not be managed similarly to negative SLN patients. Our 
results sui;gest that micro-anatomie location according to 
Dewar is not a useful tool for predicting survival and the 
NSLN status 
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